Determination of Serum Differential Carnitine Ester Levels in HIV(+) Patients : A Cross-Sectional Study
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net..
OBJECTIVE: It has been reported that carnitine deficiency is observed in various viral infections and in the follow-up of the prognosis of some diseases. In this cross-sectional study, we aimed to determine how carnitine ester derivatives change in HIV-positive patients.
MATERIALS AND METHODS: In this study, 25 HIV-infected patients who applied to Harran University Faculty of Medicine Education Research and Practice Hospital Infectious Diseases and Clinical Microbiology Outpatient Clinic and who did not receive any antiretroviral treatment, as well as 25 healthy volunteers were included in the study. Carnitine ester levels in serum samples were measured by Liquid Chromatography-Mass Spectrometry/Mass Spectrometry (LC-MS/MS) method (Shimadzu North America, Columbia, MD, USA).
RESULTS: While suberoylcarnitine (C8DC), myristoleylcarnitine (C14:1), tetradecadienoylcarnitine (C14:2), palmitoleylcarnitine (C16:1), and linoleylcarnitine (C18:2) levels in HIV(+) patients were quite low compared to the control group, tiglylcarnitine (C5:1) levels were high (p ≤ 0.05). In addition, C5:1 and C14:2 index parameters according to VIP score, and C5:1 and C14:1/C16 index parameters according to ROC analysis were determined as markers with high potential to distinguish HIV(+) patients from healthy volunteers.
CONCLUSION: This study showed that levels of acylcarnitine derivatives might be altered in HIV(+) patients, and the results obtained may contribute to a better understanding of carnitine metabolism.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:21 |
|---|---|
| Enthalten in: |
Current HIV research - 21(2023), 1 vom: 16., Seite 18-26 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Binici, Irfan [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
AIDS |
|---|
| Anmerkungen: |
Date Completed 16.05.2023 Date Revised 22.06.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.2174/1570162X21666221219141016 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM350493359 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM350493359 | ||
| 003 | DE-627 | ||
| 005 | 20231226045127.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2174/1570162X21666221219141016 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1168.xml |
| 035 | |a (DE-627)NLM350493359 | ||
| 035 | |a (NLM)36537597 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Binici, Irfan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Determination of Serum Differential Carnitine Ester Levels in HIV(+) Patients |b A Cross-Sectional Study |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.05.2023 | ||
| 500 | |a Date Revised 22.06.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net. | ||
| 520 | |a OBJECTIVE: It has been reported that carnitine deficiency is observed in various viral infections and in the follow-up of the prognosis of some diseases. In this cross-sectional study, we aimed to determine how carnitine ester derivatives change in HIV-positive patients | ||
| 520 | |a MATERIALS AND METHODS: In this study, 25 HIV-infected patients who applied to Harran University Faculty of Medicine Education Research and Practice Hospital Infectious Diseases and Clinical Microbiology Outpatient Clinic and who did not receive any antiretroviral treatment, as well as 25 healthy volunteers were included in the study. Carnitine ester levels in serum samples were measured by Liquid Chromatography-Mass Spectrometry/Mass Spectrometry (LC-MS/MS) method (Shimadzu North America, Columbia, MD, USA) | ||
| 520 | |a RESULTS: While suberoylcarnitine (C8DC), myristoleylcarnitine (C14:1), tetradecadienoylcarnitine (C14:2), palmitoleylcarnitine (C16:1), and linoleylcarnitine (C18:2) levels in HIV(+) patients were quite low compared to the control group, tiglylcarnitine (C5:1) levels were high (p ≤ 0.05). In addition, C5:1 and C14:2 index parameters according to VIP score, and C5:1 and C14:1/C16 index parameters according to ROC analysis were determined as markers with high potential to distinguish HIV(+) patients from healthy volunteers | ||
| 520 | |a CONCLUSION: This study showed that levels of acylcarnitine derivatives might be altered in HIV(+) patients, and the results obtained may contribute to a better understanding of carnitine metabolism | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a AIDS | |
| 650 | 4 | |a HIV | |
| 650 | 4 | |a LC-MS/MS | |
| 650 | 4 | |a acylcarnitine | |
| 650 | 4 | |a carnitine | |
| 650 | 4 | |a ester of carnitine | |
| 650 | 7 | |a acylcarnitine |2 NLM | |
| 650 | 7 | |a Carnitine |2 NLM | |
| 650 | 7 | |a S7UI8SM58A |2 NLM | |
| 650 | 7 | |a Esters |2 NLM | |
| 700 | 1 | |a Akbay, Halil İbrahim |e verfasserin |4 aut | |
| 700 | 1 | |a Huyut, Zübeyir |e verfasserin |4 aut | |
| 700 | 1 | |a Alp, Hamit Hakan |e verfasserin |4 aut | |
| 700 | 1 | |a Karsen, Hasan |e verfasserin |4 aut | |
| 700 | 1 | |a Koyuncu, Ismail |e verfasserin |4 aut | |
| 700 | 1 | |a Gonel, Ataman |e verfasserin |4 aut | |
| 700 | 1 | |a Akmeşe, Şükrü |e verfasserin |4 aut | |
| 700 | 1 | |a Çelik, Hakim |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current HIV research |d 2003 |g 21(2023), 1 vom: 16., Seite 18-26 |w (DE-627)NLM147412226 |x 1873-4251 |7 nnns |
| 773 | 1 | 8 | |g volume:21 |g year:2023 |g number:1 |g day:16 |g pages:18-26 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2174/1570162X21666221219141016 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 21 |j 2023 |e 1 |b 16 |h 18-26 | ||